Biomind Labs Inc (BMND) - Total Assets
Based on the latest financial reports, Biomind Labs Inc (BMND) holds total assets worth CA$57.72K CAD (≈ $41.75K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BMND total equity for net asset value and shareholders' equity analysis.
Biomind Labs Inc - Total Assets Trend (2021–2024)
This chart illustrates how Biomind Labs Inc's total assets have evolved over time, based on quarterly financial data.
Biomind Labs Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Biomind Labs Inc's total assets of CA$57.72K consist of 51.3% current assets and 48.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0.4% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Biomind Labs Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BMND company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomind Labs Inc's current assets represent 51.3% of total assets in 2024, a decrease from 96.5% in 2021.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 89.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomind Labs Inc Competitors by Total Assets
Key competitors of Biomind Labs Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Biomind Labs Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.02 | 0.69 |
| Quick Ratio | 0.04 | 0.02 | 0.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-1.56 Million | CA$-1.54 Million | CA$-30.46K |
Biomind Labs Inc - Advanced Valuation Insights
This section examines the relationship between Biomind Labs Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 117.59 |
| Latest Market Cap to Assets Ratio | 169.61 |
| Asset Growth Rate (YoY) | -44.5% |
| Total Assets | CA$41.16K |
| Market Capitalization | $6.98 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biomind Labs Inc's assets at a significant premium (169.61x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Biomind Labs Inc's assets decreased by 44.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomind Labs Inc (2021–2024)
The table below shows the annual total assets of Biomind Labs Inc from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$41.16K ≈ $29.78K |
-44.53% |
| 2023-12-31 | CA$74.20K ≈ $53.67K |
-16.69% |
| 2022-12-31 | CA$89.06K ≈ $64.43K |
-96.48% |
| 2021-12-31 | CA$2.53 Million ≈ $1.83 Million |
-- |
About Biomind Labs Inc
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more